Wockhardt Limited (WOCKPHARMA) receives CDSCO approval for Zaynich® antibiotic for treating complicated urinary tract infections.
Supriya Lifescience Limited (SUPRIYA) reports a 50% YoY revenue surge in Q4 FY26, driven by strong performance across therapeutic segments.
Hikal Limited (HIKAL) announces Q4 FY26 earnings with revenue at ₹519 crore, EBITDA margin at 20.3%, and PAT at ₹14 crore.
FDC Limited (NSE: FDC) announces Q4 FY26 results with PAT up 167.4% and revenue growth of 18.9%. Detailed financial performance and segment analysis.
Max India Limited (MAXIND) announces Antara Senior Care's occupancy certificate for Noida Sector 150 Phase 1, enabling 340 senior families to possess homes.
Morepen Laboratories Limited (MOREPENLAB) reports a 69% YoY net profit rise in Q4 FY26, with gross revenue up 22% to Rs. 472 Cr.
AstraZeneca Pharma India Limited (ASTRAZEN) reports a consistent 33% growth in FY 2025-26, with total revenue reaching INR 22,755.8 Mn.
Sun Pharma to present long-term follow-up data on UNLOXCYT™ at ASCO 2026, showing nearly 27% complete response rate.
Marksans Pharma Limited (MARKSANS) reported Q4 & FY26 financial results with historic triple: highest revenue, EBITDA & PAT ₹3,000 Cr.
Gujarat Themis Biosyn Limited (GUJTHEM) reports Q4 FY26 results with 17% revenue growth, margin expansion, and strategic acquisitions.